Systemic approach to improving treatment outcome in nasopharyngeal carcinoma: Current and future directions

Systemic therapy is an integral part of the management of non‐keratinizing nasopharyngeal carcinoma (NPC). The purposes of this review are to provide the latest results and future directions of clinical and translational research for this disease, and to illustrate how some of these new therapies ha...

Full description

Saved in:
Bibliographic Details
Published in:Cancer science 2008-07, Vol.99 (7), p.1311-1318
Main Authors: Ma, Brigette B. Y., Hui, Edwin P., Chan, Anthony T. C.
Format: Article
Language:English
Subjects:
Biological and medical sciences
Cell Hypoxia
Chemotherapy
Chemotherapy, Adjuvant
Clinical outcomes
Cytotoxicity
DNA Methylation
Epstein-Barr virus
Histone Deacetylase Inhibitors
Humans
Immunotherapy, Adoptive
Medical sciences
Metastasis
Nasopharyngeal carcinoma
Nasopharyngeal Neoplasms - therapy
Otorhinolaryngology. Stomatology
Palliative Care
Patients
Protein Kinase Inhibitors - therapeutic use
Radiation therapy
Review
Studies
Tumors
Upper respiratory tract, upper alimentary tract, paranasal sinuses, salivary glands: diseases, semeiology
Vascular Endothelial Growth Factor A - antagonists & inhibitors
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Systemic therapy is an integral part of the management of non‐keratinizing nasopharyngeal carcinoma (NPC). The purposes of this review are to provide the latest results and future directions of clinical and translational research for this disease, and to illustrate how some of these new therapies have improved the treatment outcome for patients with NPC. Particular attention will be paid to the clinical application of chemotherapy in the adjunctive treatment of locoregionally advanced NPC, novel targeted drugs, Epstein–Barr virus‐targeted vaccine therapies, and the use of plasma Epstein–Barr virus DNA as a biomarker for selecting patients for adjunctive therapies. (Cancer Sci 2008; 99: 1311–1318)
ISSN:1347-9032
1349-7006
1349-7006
DOI:10.1111/j.1349-7006.2008.00836.x